AR104358A1 - Método para la purificación de proteínas - Google Patents
Método para la purificación de proteínasInfo
- Publication number
- AR104358A1 AR104358A1 ARP160101122A ARP160101122A AR104358A1 AR 104358 A1 AR104358 A1 AR 104358A1 AR P160101122 A ARP160101122 A AR P160101122A AR P160101122 A ARP160101122 A AR P160101122A AR 104358 A1 AR104358 A1 AR 104358A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- domain
- human
- protein
- antibody containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para obtener un anticuerpo que contiene el dominio VH3 humano en forma monomérica, que comprende: a) aplicar una mezcla qua comprende un anticuerpo que contiene el dominio VH3 humano en forma monomérica y multimérica a un material de cromatografía de proteína A donde dicha proteína A comprende el dominio D y/o E, bajo condiciones que permiten la unión de dicho anticuerpo a la proteína A, y b) recuperar el anticuerpo que contiene el dominio VH3 humano en forma monomérica, donde el anticuerpo que contiene el dominio VH3 humano no contiene una región Fc. Reivindicación 2: Un método para fabricar un anticuerpo que contiene el dominio VH3 humano qua comprende: a) expresar el anticuerpo en una célula huésped, b) recuperar una mezcla que contiene el anticuerpo, células huésped y otros contaminantes, c) purificar el anticuerpo utilizando al menos una etapa de cromatografía de proteína A donde dicha proteína A comprende el dominio D y/o E, y d) recuperar el anticuerpo que contiene el dominio VH3 humano, donde el anticuerpo que contiene el dominio VH3 humano no contiene una región Fc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506868.7A GB201506868D0 (en) | 2015-04-22 | 2015-04-22 | Method for protein purification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104358A1 true AR104358A1 (es) | 2017-07-12 |
Family
ID=53299017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101122A AR104358A1 (es) | 2015-04-22 | 2016-04-22 | Método para la purificación de proteínas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10927164B2 (es) |
| EP (1) | EP3286205A1 (es) |
| JP (2) | JP6866300B2 (es) |
| KR (1) | KR20170139131A (es) |
| CN (1) | CN107636012B (es) |
| AR (1) | AR104358A1 (es) |
| AU (1) | AU2016251223B2 (es) |
| BR (1) | BR112017022073A2 (es) |
| CA (1) | CA2983057A1 (es) |
| CL (1) | CL2017002614A1 (es) |
| CO (1) | CO2017010631A2 (es) |
| EA (1) | EA201792328A1 (es) |
| GB (1) | GB201506868D0 (es) |
| IL (1) | IL254883B (es) |
| MA (1) | MA41941A (es) |
| MX (1) | MX2017013333A (es) |
| MY (1) | MY189854A (es) |
| SG (1) | SG11201708256YA (es) |
| WO (1) | WO2016169992A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9657055B2 (en) * | 2011-11-30 | 2017-05-23 | Ge Healthcare Bioprocess R&D Ab | Affinity chromatography matrix |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| CN108085358A (zh) * | 2018-02-08 | 2018-05-29 | 保定冀中药业有限公司 | 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法 |
| CA3142610A1 (en) | 2019-08-02 | 2021-02-11 | UCB Biopharma SRL | Methods for purifying antibodies |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| BR112022011993A2 (pt) * | 2019-12-26 | 2022-09-20 | Abl Bio Inc | Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP1181052A4 (en) | 1999-05-15 | 2004-08-11 | Univ California San Diego | AREAS WITH INTENDED ACTIVITIES BASED ON PROTEIN A |
| CN100374456C (zh) * | 2000-12-29 | 2008-03-12 | 萨文特医药公司 | 用于选择性癌症治疗的特异性人抗体 |
| EP1614693A4 (en) * | 2003-03-31 | 2006-07-19 | Kirin Brewery | PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY |
| CA2733782A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| AU2010216152B2 (en) * | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| EA201300524A1 (ru) * | 2010-11-01 | 2013-08-30 | ДСМ АйПи АССЕТС Б.В. | Очистка антител ионообменной хроматографией в едином блоке |
| WO2012074463A1 (en) | 2010-11-29 | 2012-06-07 | Ge Healthcare Bio-Sciences Ab | Affinity chromatography matrix |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| CA2856216C (en) | 2011-11-11 | 2021-01-12 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
| WO2013119966A2 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| SG10201909806SA (en) * | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2015
- 2015-04-22 GB GBGB1506868.7A patent/GB201506868D0/en not_active Ceased
-
2016
- 2016-04-20 BR BR112017022073A patent/BR112017022073A2/pt active Search and Examination
- 2016-04-20 CN CN201680028589.3A patent/CN107636012B/zh active Active
- 2016-04-20 MA MA041941A patent/MA41941A/fr unknown
- 2016-04-20 JP JP2017555232A patent/JP6866300B2/ja active Active
- 2016-04-20 MX MX2017013333A patent/MX2017013333A/es unknown
- 2016-04-20 MY MYPI2017703933A patent/MY189854A/en unknown
- 2016-04-20 US US15/566,231 patent/US10927164B2/en active Active
- 2016-04-20 SG SG11201708256YA patent/SG11201708256YA/en unknown
- 2016-04-20 EP EP16717915.9A patent/EP3286205A1/en active Pending
- 2016-04-20 EA EA201792328A patent/EA201792328A1/ru unknown
- 2016-04-20 KR KR1020177033687A patent/KR20170139131A/ko active IP Right Grant
- 2016-04-20 AU AU2016251223A patent/AU2016251223B2/en active Active
- 2016-04-20 CA CA2983057A patent/CA2983057A1/en active Pending
- 2016-04-20 WO PCT/EP2016/058774 patent/WO2016169992A1/en active Application Filing
- 2016-04-22 AR ARP160101122A patent/AR104358A1/es unknown
-
2017
- 2017-10-03 IL IL254883A patent/IL254883B/en unknown
- 2017-10-16 CL CL2017002614A patent/CL2017002614A1/es unknown
- 2017-10-18 CO CONC2017/0010631A patent/CO2017010631A2/es unknown
-
2021
- 2021-01-07 JP JP2021001584A patent/JP2021066734A/ja not_active Abandoned
- 2021-02-17 US US17/177,236 patent/US20210171609A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017002614A1 (es) | 2018-04-27 |
| EP3286205A1 (en) | 2018-02-28 |
| BR112017022073A2 (pt) | 2018-08-14 |
| KR20170139131A (ko) | 2017-12-18 |
| IL254883B (en) | 2021-09-30 |
| JP2018520089A (ja) | 2018-07-26 |
| JP2021066734A (ja) | 2021-04-30 |
| GB201506868D0 (en) | 2015-06-03 |
| US10927164B2 (en) | 2021-02-23 |
| US20180100007A1 (en) | 2018-04-12 |
| CN107636012B (zh) | 2022-08-02 |
| US20210171609A1 (en) | 2021-06-10 |
| MY189854A (en) | 2022-03-14 |
| AU2016251223A1 (en) | 2017-10-26 |
| CN107636012A (zh) | 2018-01-26 |
| WO2016169992A1 (en) | 2016-10-27 |
| AU2016251223B2 (en) | 2021-12-09 |
| IL254883A0 (en) | 2017-12-31 |
| EA201792328A1 (ru) | 2018-05-31 |
| SG11201708256YA (en) | 2017-11-29 |
| CO2017010631A2 (es) | 2018-01-05 |
| JP6866300B2 (ja) | 2021-04-28 |
| MA41941A (fr) | 2018-02-28 |
| MX2017013333A (es) | 2018-02-19 |
| CA2983057A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104358A1 (es) | Método para la purificación de proteínas | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| EA201790247A1 (ru) | Платформа для очистки биспецифичных антител | |
| CO2017005639A2 (es) | Anticuerpos anti-miostatina, polipéptidos que contienen regiones fc variantes | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| ES2743232T3 (es) | Métodos para la activación o eliminación controlada de células terapéuticas | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| EA201790719A1 (ru) | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| CU20170039A7 (es) | Método de purificación del anticuerpo humanizado 9e4 | |
| EA201892774A1 (ru) | Антитела | |
| CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| BR112016008125A2 (pt) | moléculas de ligação de domínio de fibronectina tipo iii modificadas com cisteína | |
| EA201690503A1 (ru) | Антитела | |
| MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
| EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
| CL2020000087A1 (es) | Cromatografía. | |
| SG10201807572PA (en) | Robust antibody purification |